18PTKI pazopanib impaires immunostimulatory properties of monocytes: Implication for monocyte-derived DC-based anti-cancer vaccine preparation

ZDRAŽILOVÁ DUBSKÁ, Lenka, Lenka FĚDOROVÁ, Kateřina PILÁTOVÁ, Peter MÚDRY, Eva HLAVÁČKOVÁ, Eva MATOULKOVÁ, Lucie FLAJŠAROVÁ, Regina DEMLOVÁ, Dalibor VALÍK and Jaroslav ŠTĚRBA. 18PTKI pazopanib impaires immunostimulatory properties of monocytes: Implication for monocyte-derived DC-based anti-cancer vaccine preparation. ISSN 0923-7534. doi:10.1093/annonc/mdw525.18. 2016.

Basic information

• Original name: 18PTKI pazopanib impaires immunostimulatory properties of monocytes: Implication for monocyte-derived DC-based anti-cancer vaccine preparation
• Authors: ZDRAŽILOVÁ DUBSKÁ, Lenka (203 Czech Republic, guarantor, belonging to the institution), Lenka FĚDOROVÁ (203 Czech Republic), Kateřina PILÁTOVÁ (203 Czech Republic, belonging to the institution), Peter MÚDRY (203 Czech Republic), Eva HLAVÁČKOVÁ (203 Czech Republic), Eva MATOULKOVÁ (203 Czech Republic, belonging to the institution), Lucie FLAJŠAROVÁ (203 Czech Republic, belonging to the institution), Regina DEMLOVÁ (203 Czech Republic, belonging to the institution), Dalibor VALÍK (203 Czech Republic, belonging to the institution) and Jaroslav ŠTĚRBA (203 Czech Republic).
• Edition: 2016.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 30204 Oncology
• Country of publisher: Netherlands
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 11.855
• RIV identification code: RIV/00216224:14110/16:00114976
• Organization unit: Faculty of Medicine
• ISSN: 0923-7534
• Doi: http://dx.doi.org/10.1093/annonc/mdw525.18
• Keywords in English: cancer monocytes vaccines protein-tyrosine kinase inhibitor pazopanib
• Tags: rivok
• Tags: International impact

Abstract

We manufacture fully personalized monocyte-derived dendritic cell-based vaccines that are evaluated in investigator-initiated clinical trial „Combined antitumor therapy with ex vivo manipulated dendritic cells producing interleukin-12 in children, adolescents and young adults with progressive, recurrent of primarily metastatic high-risk tumours”. Immunobiological part of quality control (QC) of DC batches revealed variability in immunostimulatory properties. We analyzed DC parametres within the context of patients medical history and explore the effect of anti-cancer compound on monocyte functional properties.

Links

• LM2015090, research and development project: Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)

Investor: Ministry of Education, Youth and Sports of the CR